RP 116
Alternative Names: RP-116Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator ViroCure
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Head and neck cancer; Prostate cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Head-and-neck-cancer in South Korea
- 28 Sep 2024 No recent reports of development identified for preclinical development in Prostate-cancer in South Korea
- 19 Aug 2020 Virocure plans to file for orphan drug designation for RP 116 (Virocure pipeline, September 2020)